000164202 001__ 164202
000164202 005__ 20240320110017.0
000164202 0247_ $$2doi$$a10.3233/JAD-210286
000164202 0247_ $$2pmid$$apmid:34250938
000164202 0247_ $$2ISSN$$a1387-2877
000164202 0247_ $$2ISSN$$a1875-8908
000164202 0247_ $$2altmetric$$aaltmetric:109249654
000164202 037__ $$aDZNE-2022-00858
000164202 041__ $$aEnglish
000164202 082__ $$a610
000164202 1001_ $$aZebhauser, Paul Theo$$b0
000164202 245__ $$aAge-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-β 1-40: A Correlational Study in Healthy Adults.
000164202 260__ $$aAmsterdam$$bIOS Press$$c2021
000164202 3367_ $$2DRIVER$$aarticle
000164202 3367_ $$2DataCite$$aOutput Types/Journal article
000164202 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710928772_2065
000164202 3367_ $$2BibTeX$$aARTICLE
000164202 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164202 3367_ $$00$$2EndNote$$aJournal Article
000164202 520__ $$aTau proteins are established biomarkers of neuroaxonal damage in a wide range of neurodegenerative conditions. Although measurement of total-Tau in the cerebrospinal fluid is widely used in research and clinical settings, the relationship between age and total-Tau in the cerebrospinal fluid is yet to be fully understood. While past studies reported a correlation between age and total-Tau in the cerebrospinal fluid of healthy adults, in clinical practice the same cut-off value is used independently of patient's age.To further explore the relationship between age and total-Tau and to disentangle neurodegenerative from drainage-dependent effects.We analyzed cerebrospinal fluid samples of 76 carefully selected cognitively healthy adults and included amyloid-β 1-40 as a potential marker of drainage from the brain's interstitial system.We found a significant correlation of total-Tau and age, which was no longer present when correcting total-Tau for amyloid-β 1-40 concentrations. These findings were replicated under varied inclusion criteria.Results call into question the association of age and total-Tau in the cerebrospinal fluid. Furthermore, they suggest diagnostic utility of amyloid-β 1-40 as a possible proxy for drainage-mechanisms into the cerebrospinal fluid when interpreting biomarker concentrations for neurodegenerative diseases.
000164202 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164202 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164202 650_7 $$2Other$$aAlzheimer’s disease
000164202 650_7 $$2Other$$aamyloid-beta 1–40
000164202 650_7 $$2Other$$atau proteins
000164202 650_7 $$2Other$$atotal-Tau
000164202 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000164202 650_7 $$2NLM Chemicals$$aBiomarkers
000164202 650_7 $$2NLM Chemicals$$aPeptide Fragments
000164202 650_7 $$2NLM Chemicals$$aamyloid beta-protein (1-40)
000164202 650_7 $$2NLM Chemicals$$atau Proteins
000164202 650_2 $$2MeSH$$aAge Factors
000164202 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000164202 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000164202 650_2 $$2MeSH$$aFemale
000164202 650_2 $$2MeSH$$aHealthy Volunteers: statistics & numerical data
000164202 650_2 $$2MeSH$$aHumans
000164202 650_2 $$2MeSH$$aMale
000164202 650_2 $$2MeSH$$aMiddle Aged
000164202 650_2 $$2MeSH$$aModels, Statistical
000164202 650_2 $$2MeSH$$aPeptide Fragments: cerebrospinal fluid
000164202 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000164202 7001_ $$aBerthele, Achim$$b1
000164202 7001_ $$aFranz, Marie-Sophie$$b2
000164202 7001_ $$aGoldhardt, Oliver$$b3
000164202 7001_ $$0P:(DE-2719)2811585$$aDiehl-Schmid, Janine$$b4$$udzne
000164202 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b5$$udzne
000164202 7001_ $$aOrtner, Marion$$b6
000164202 7001_ $$aGrimmer, Timo$$b7
000164202 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-210286$$gVol. 83, no. 1, p. 155 - 162$$n1$$p155 - 162$$tJournal of Alzheimer's disease$$v83$$x1387-2877$$y2021
000164202 8564_ $$uhttps://pub.dzne.de/record/164202/files/DZNE-2022-00858_Restricted.pdf
000164202 8564_ $$uhttps://pub.dzne.de/record/164202/files/DZNE-2022-00858_Restricted.pdf?subformat=pdfa$$xpdfa
000164202 909CO $$ooai:pub.dzne.de:164202$$pVDB
000164202 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811585$$aExternal Institute$$b4$$kExtern
000164202 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000164202 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164202 9141_ $$y2021
000164202 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000164202 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000164202 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000164202 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2021$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-18
000164202 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-18
000164202 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x0
000164202 980__ $$ajournal
000164202 980__ $$aVDB
000164202 980__ $$aI:(DE-2719)5000007
000164202 980__ $$aUNRESTRICTED